Table 2.
Doses of Ganciclovir and Valganciclovir in the studied population at different dosing times during patient's hospitalization.
| Doses at different dosing times ∗ |
Prophylaxis of CMV infection
£ (N = 37) |
Treatment of CMV disease (N = 111) |
||
|---|---|---|---|---|
| Ganciclovir | Valganciclovir | Ganciclovir | Valganciclovir | |
| First administered dose | 2.1 ± 1.3 | 411.0 ± 117.8 | 2.8 ± 1.6 | 512.1 ± 184.5 |
| First optimal dose | 1.2 ± 0.9 | 285.0 ± 183.4 | 1.8 ± 1.2 | 400.2 ± 201.7 |
| Appropriateness of administered dose compared to optimal dose ∗∗ | 18.1% | 38.5% | 24.8% | 43.2% |
| Second administered dose | 2.4 ± 1.5 | 456.4 ± 206.2 | 3.1 ± 0.9 | 571.9 ± 214.8 |
| Second optimal dose | 2.0 ± 1.1 | 409.0 ± 193.4 | 2.7 ± 1.8 | 510.0 ± 321.3 |
| Appropriateness of administered dose compared to optimal dose | 29.5% | 47.5% | 32.4% | 41.3% |
| Third administered dose | 2.9 ± 2.1 | 508.8 ± 198.2 | 3.4 ± 1.9 | 684.1 ± 244.5 |
| Third optimal dose | 2.3 ± 1.6 | 412.6 ± 187.5 | 3.0 ± 2.1 | 625.0 ± 270.4 |
| Appropriateness of administered dose compared to optimal dose | 25.2% | 31.6% | 29.7% | 28.0% |
Data presented as mean ± SD of drugs' doses or % of the patients who received the appropriate dose.
∗ Doses are based on mg/day for Valganciclovir and mg/kg/day for Ganciclovir.
∗∗ The administered dose is considered appropriate if it was within the range of 80-120% of the optimal dose.
£ In patients receiving antiviral therapy as a part of transplantation regimen, after transplantation surgery.